Evidence map›Paper›PMID 40248548›Full record

ReviewCureus2025

Efficacy and Safety of Cannabinoids for Autism Spectrum Disorder: An Updated Systematic Review.

Danilo A Pereira, Lidia Cheidde, Mateus Daniel R Megiolaro, Ana Elisa F Camargo, Elizabet Taylor P Weba, Victor G Soares, Anderson M Pereira da Silva, Laura Cheidde, Pedro Paulo Ladeira Júnior, Dillan C Amaral and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Novel therapeutics in autism spectrum disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Danilo A PereiraDepartment of Human Reproduction and Childhood, Pontifícia Universidade Católica de São Paulo, Sorocaba, BRA.
Lidia CheiddeFaculty of Medicine, Pontifícia Universidade Católica de São Paulo, Sorocaba, BRA.
Mateus Daniel R MegiolaroFaculty of Medicine, Pontifícia Universidade Católica de São Paulo, Sorocaba, BRA.
Ana Elisa F CamargoFaculty of Medicine, Pontifícia Universidade Católica de São Paulo, Sorocaba, BRA.
Elizabet Taylor P WebaFaculty of Medicine, Universidade Estadual da Região Tocantina do Maranhão, Imperatriz, BRA.
Victor G SoaresFaculty of Medicine, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, BRA.
Anderson M Pereira da SilvaDepartment of Pharmacology, Universidade Federal do Vale do São Francisco, Petrolina, BRA.
Laura CheiddeDepartment of Orthopaedics and Trauma, Universidade Cidade de São Paulo (UNICID), São Paulo, BRA.
Pedro Paulo Ladeira JúniorFaculty of Medicine, Universidade Cidade de São Paulo (UNICID), São Paulo, BRA.
Dillan C AmaralFaculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRA.
Rafael TriacaFaculty of Medicine, Universidade Unigranrio Escola de Ciências da Saúde, Duque de Caxias, BRA.
Matheus Augusto N FernandesFaculty of Medicine, Universidade Anhembi Morumbi, São José dos Campos, BRA.
Paula Maria P MimuraDepartment of Specialized Rehabilitation, Hospital Estadual Especializado em Reabilitação "Dr. Francisco Ribeiro Arantes", Itu, BRA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) lacks an established pharmacological treatment protocol, prompting interest in alternative therapeutic approaches, such as cannabidiol (CBD). This systematic review evaluates the potential efficacy and safety of CBD-rich formulations in managing ASD symptoms. A comprehensive search of PubMed, Embase, Scopus, Web of Science, and the Cochrane Library identified seven studies encompassing 494 patients from Brazil and Israel. Preliminary findings suggest that CBD-rich formulations may provide modest benefits for sleep and social interaction, with a reduction in anxiety symptoms. Regarding core ASD symptoms and behavioral outcomes, cannabinoids demonstrated greater efficacy compared to placebo in some studies. However, adverse events varied, and response to treatment was inconsistent across individuals. While cannabinoids, particularly CBD-rich formulations, appear to be relatively safe and potentially beneficial, further large-scale, controlled trials comparing CBD to established ASD treatments are essential to clarify its role and long-term impact in ASD management.

Indexed as

a systematic reviewautism spectrum disordercannabinoidsefficacysafety

Identifiers

PMID40248548
PMCPMC12005571

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.